🚨 Thrilled to share our @JCO_ASCO publication from the ACCESS study! Honored to co-chair this pivotal work at @cityofhope with @CIBMTR & @nmdp_org—advancing access to life-saving #BMT 🔗 https://t.co/K0qZe0Jre5 🔗

Proud to share @JCO_ASCO paper of the ACCESS study run by @CIBMTR and sponsored by @nmdp_org 145 recipients of MMUD grafts using PTCy experienced outcomes similar to matched transplants, including <7/8 grafts. 59% of patients were diverse!

Celebrating record-high with 20,000 transplant @cityofhope https://t.co/uKWyjHmGCK

AlloHeme Enhances Early Relapse Detection in AML and MDS Post-Transplant https://t.co/1CebHUbNCl via @targetedonc @cityofhope

Monzr M. Al Malki, MD, of @cityofhope discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation. Watch more here: https://t.co/rj1NQR4DcM

Tune in to hear @DrMonzrAlMalki of @cityofhope and @JeffAuletta of @NMDP_org discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies. Watch here:

CONGRESS | #Tandem25 @DrMonzrAlMalki @cityofhope presented results from the ACCESS study which assessed PTCy for #GvHD prophylaxis after MMUD PBSC. 1-year OS was 84%, 56% of pts experienced Grade 2-5 infection in the first 100 days post-transplant. https://t.co/7whprdsds2

CONGRESS | #Tandem25 | PRESENTATION @DrMonzrAlMalki, @cityofhope, presents preliminary results from the phase I ALLOHA trial (NCT05473910) evaluating TSC-100 and TSC-101 TCR-T cells as maintenance treatment post-HCT to prevent relapse in patients with AML, ALL, or MDS undergoing

CONGRESS | #Tandem25 @DrMonzrAlMalki, @cityofhope presented results from the phase I Alloha trial of TSC-100 & TSC-101 in #AML, #ALL and #MDS post allo-HCT. Infusions were well tolerated with no DLTs. 8% of TSC treated pts relapsed vs 33% in the control arm.

Novel engineered Treg product TRX-101 + PTCy in mismatched alloHCT. Early phase I results presented by @DrMonzrAlMalki from @cityofhope. Is this the future of reducing IST burden? #Tandem25

Interim analysis of a very promising microchimerism NGS based testing modality “Allo-heme” on ACROBAT study in AML/MDS by @DrMonzrAlMalki #Tandem25

Heading to #Tandem25? Don’t miss oral presentations by Dr. @JeffAuletta and @cityofhope's @DrMonzrAlMalki on new ACCESS trial research tackling non-HLA barriers in cell therapy and improving all patient outcomes. 🔬 👉 https://t.co/8mnL90iXAJ 👉 https://t.co/MKqoIUlqea

⁦@DrMonzrAlMalki⁩ and PTCy in MUD at ⁦@SocietyofHemOnc⁩ Saudi Arabia ⁦@KFSHRC⁩ ⁦@cityofhope⁩

Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT) https://t.co/ESgHmtpONT #mdpicancers via @Cancers_MDPI

Just published in @JCO_ASCO: Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors | @nmdp_org

Remember when we used to avoid mismatched unrelated donor transplants for fear of worse GVHD and NRM outcomes? Those days are over. Congrats to the study team!! 🎉@CIBMTR @nmdp_org @BrianShafferMD @MGooptu @GvHD_Meade @spellman_s @amjimenezmd @DrMonzrAlMalki #PTCyrules

At #ASCO24, @DrMonzrAlMalki and @RichaThakurMD sat down to discuss Dr. Al Malki's presentation about addressing barriers to #transplantation #accessibility. Listen along to the #podcast to learn more: https://t.co/FCHZpvD39p

A DOCTOR ISN’T BORN, A DOCTOR IS MADE. @Doctors__squad #Meded #medx

New approach ‘redefining what is a suitable donor’ @ASCO @nmdp_org @cityofhope for stem cell transplant

CONGRESS #ASCO24 | @DrMonzrAlMalki, @cityofhope presented findings from the phase II ACCESS study assessing PTCy-based GVHD prophylaxis following MMUD transplantation. GRFS at 1 year was estimated at 47%, with 1 year OS of 79%. #GvHD #GvHDsm